Disease relevance of Stakan

• In a double-blind, cross-over study the efficacy of antrafenine at doses of 450 mg/day and 900 mg/day was compared to naproxen 750 mg/day and placebo in patients with osteoarthritis [1].
• Assessment of analgesic drugs in soft tissue injuries presenting to an accident and emergency department--a comparison of antrafenine, paracetamol and placebo [2].

High impact information on Stakan

• The analgesic antrafenine forms 1-m-trifluoromethylphenylpiperazine (mCF3PP) during its biotransformation in the rat and mouse [3].
• The effects of antrafenine were compared with aspirin and placebo on platelet aggregation and on the diuretic action of frusemide in normal volunteers [4].

Biological context of Stakan

• Aspirin significantly reduced platelet aggregation at 3 and 6 hr after administration, but antrafenine only at 3 hr [4].

Analytical, diagnostic and therapeutic context of Stakan

• Compound 45, 2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl 2-[[7-(trifluoromethyl)-4-quinolinyl]amino]benzoate (antrafenine), showed marked analgesic activity, long duration of action, and excellent tolerance in pharmacological and toxicological studies, as well as in clinical trials [5].
• Antrafenine was measured by high-performance liquid chromatography using a Spherisorb 5-micrometer ODS column with acetonitrile-0.1 M sodium acetate as the mobile phase [6].

References